On May 4, 2017, FDA hosted a public meeting on Patient-Focused Drug Development for Autism. FDA was interested in obtaining patient perspectives on the impact of autism on daily life and patient views on treatment approaches. For more information, visit the meeting webpage: https://go.usa.gov/xAPmG
Public Meeting: Patient-Focused Drug Development for Autism (Part 1 of 2)
